Additional file 9: of Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer

Table S6. Best overall response by lesion type (safety analysis set). (PDF 256 kb)